Co-funded by the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.

PRECISEU Best Practice Recognition

Second Edition 2026

Winner in the Category IMPACT

Altum TRACKseq

Marina Planas (Altum sequencing , S.L)

Revolutionizing cancer monitoring after diagnosis and treatment, using cutting-edge DNA sequencing we can detect a single tumor cell among a million healthy ones - from just a simple blood sample.

Altum TRACKseq is a liquid biopsy test that helps doctors monitor cancer after diagnosis and treatment. It looks for tiny traces of tumor DNA (ctDNA) in the blood to detect measurable residual disease (MRD), small amounts of cancer that may remain after treatment, and to identify relapse risk earlier.

After treatment, many patients still face a risk of recurrence. Today, follow-up often relies on imaging, which can sometimes be unclear or detect relapse only once it is more advanced. Altum TRACKseq aims to provide an earlier, more precise signal from a simple blood draw, supporting faster and better-informed clinical decisions.

This initiative focuses on follicular lymphoma, a type of blood cancer for which long-term follow-up is essential due to the high risk of relapse following first-line treatment. It has been developed in close collaboration with academic and clinical partners to accelerate its adoption in clinical practice within precision oncology care protocols.

Main objectives:

- Evaluate the clinical value of Altum TRACKseq for early detection of molecular relapse.
- Compare performance against conventional monitoring tools such as imaging.
- Support treatment decisions and improve patient risk stratification.

Altum TRACKseq uses each patient's tumor information to build a personalized monitoring test. During follow-up, blood samples are analyzed using deep DNA sequencing (NGS) and specialized data analysis. AI algorithms help reduce background noise and improve confidence in the result, and can integrate longitudinal molecular data with clinical information (e.g., treatment history, imaging results, outcomes).

Preliminary results show Altum TRACKseq can detect ctDNA months before relapse is visible on imaging in some cases, giving clinicians an earlier warning signal. The test demonstrates very high analytical sensitivity, capable of detecting extremely small tumor signals in a large background of healthy DNA.

Altum Sequencing delivers real-world clinical impact by combining academic collaboration, AI-enhanced ctDNA liquid biopsy, and longitudinal patient data to enable earlier relapse detection and more personalized monitoring in follicular lymphoma.